Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA
Introduction: Predictive value of adjuvant chemotherapy for patients with early-stage hormone receptor-positive breast cancer has been suggested by 21-gene expression assay, although its cost-effectiveness has not been well-defined. We have developed the deep learning-based H&E image analyzer named Lunit SCOPE, identifying and quantifying various histologic components from H&E-stained whole slide images We hypothesized that cell proportions analyzed by Lunit SCOPE would be a potential prognostic and predictive biomarker of adjuvant chemotherapy in early-stage hormone receptor-positive breast cancer.
Method: We have collected clinical data and H&E slides from de-identified 2,915 early breast cancer patients in Samsung Medical Center, retrospectively. The 898 patients with hormone receptor-positive, T1b ~ T3 and N0 ~ N1mi have been selected to analyze the predictive value of adjuvant chemotherapy. Deep learning-based H&E image analyzer, Lunit SCOPE, has been trained by 1,191 H&E-stained whole slide images from another breast cancer patient cohort. In the whole slide image, biological and histological components such as cancer epithelium, cancer stroma, normal, fat, necrosis, lymphocyte, fibroblast, and other cells, have been annotated by over 10 pathologists. The outputs of Lunit SCOPE are the ratio of cancer epithelium, cancer stroma, normal, necrosis and fat in a whole slide image and intratumoral tumor infiltrating lymphocyte (TIL) and stromal TIL density. The recurrence score (RS) based on the output of Lunit SCOPE has been determined by using multivariate cox regression analysis for disease-free survival (DFS) in the patients without adjuvant chemotherapy.
Result: Recurrence score (RS) was proportional to the cancer stroma ratio and stromal TIL density, but inversely proportional to intratumoral TIL density. When the RS cutoff was 0.913, 21.3% (191 out of 898) of patients were classified as high risk group (RS > cutoff). Among those without adjuvant chemotherapy, high risk group presented poor DFS (hazard ratio [HR] 4.23, 95% confidence interval [CI] 1.87-9.59, P = 1.73 x 10-4) and overall survival (OS, HR 4.95, 95% CI 1.39-17.6, P = 6.07 x 10-3) than the low risk group. Adjuvant chemotherapy did not prolong OS in patients with low risk group (HR 1.08, 95% CI 0.38-3.12, P = 0.885). However, interestingly, in those with high risk by Lunit SCOPE, adjuvant chemotherapy prolonged DFS (HR 0.35, 95% CI 0.15-0.86, P = 0.0161) and OS (HR 0.22, 95% CI 0.05-0.95, P = 0.0254), reflecting RS by Lunit SCOPE would be a significant predictive biomarker of adjuvant chemotherapy.
Conclusion: Deep learning-based H&E image analyzer, Lunit SCOPE, was possible to analyze the prognosis of breast cancer. Especially, only high risk patients of RS by Lunit SCOPE had survival benefit from adjuvant chemotherapy, which needs to be validated in clinical trials.
Citation Format: Soo Youn Cho, Eun Yoon Cho, Kyunghyun Paeng, Geunyoung Jung, Sarah Lee, Sang Yong Song. Deep learning-based predictive biomarker for adjuvant chemotherapy in early-stage hormone receptor-positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3144.
Soo Youn Cho, Eun Yoon Cho, Kyunghyun Paeng, Geunyoung Jung, Sarah Lee and Sang Yong Song
Abstract: Pan-cancer analysis of tumor microenvironment using deep learning-based cancer stroma and immune profiling in H&E images
Abstract: Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer
Abstract: Comprehensive deep learning analysis of H&E tissue phenomics reveals distinct immune landscape and transcriptomic enrichment profile among immune inflamed, excluded and desert subtypes...
Abstract: Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor...
Abstract: Deep learning-based immune phenotype analysis reveals distinct resistance pattern of immune checkpoint inhibitor in non-small cell lung cancer
Reducing Domain Gap by Reducing Style Bias
Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge
Accuracy and efficiency of an artificial intelligence tool when counting breast mitoses
Abstract: Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes (TIL) to reflect target gene expressions of novel immuno-oncology agents.
Abstract: Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by ...
Abstract : Pathologic validation of artificial intelligence-powered prediction of combined positive score of PD-L1 immunohistochemistry in urothelial carcinoma.
Abstract : Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) ...
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
Abstract : Deep learning based radiomic biomarker for predicting the presence of high-grade histologic patterns in lung adenocarcinoma
Abstract : Artificial intelligence-powered tissue analysis reveals distinct tumor-infiltrating lymphocyte profile as a potential biomarker of molecular subtypes in endometrial cancer
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals distinct genomic profile of immune excluded phenotype in pan-carcinoma
Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
Using artificial intelligence to read chest radiographs for tuberculosis detection: A multi-site evaluation of the diagnostic accuracy of three deep learning systems
Abstract : Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Abstract : Assistance with an artificial intelligence-powered PD-L1 analyzer reduces interobserver variation in pathologic reading of tumor proportion score in non-small cell lung cancer
Abstract : AI-powered whole-slide image analysis of tumor-infiltrating lymphocytes for prediction of prognosis in colorectal cancer
Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Artificial Intelligence–Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Non–Small-Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Analyzer Reduces Inter-observer Variation in PD-L1 Tumor Proportion Score of Non-Small Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Tumor Purity Assessment From H&E Whole Slide Images Correlates...
Abstract : Deep learning-based H&E analyzer reveals distinct immune profiles and clinical outcomes among immune phenotypes in uterine corpus endometrial carcinoma
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals immune-excluded phenotype is correlated with TGF-beta pathway related genomic aberrations
Observer Performance Study to Examine the Feasibility of the AI-powered PD-L1 Analyzer to Assist Pathologists’ Assessment of PD-L1 Expression Using Tumor Proportion Score in Non-Small Cell Lung Cancer
Artificial intelligence-powered human epidermal growth factor receptor 2 (HER2) analyzer in breast cancer as an assistance tool for pathologists to reduce interobserver variation
Artificial intelligence-powered whole-slide image analyzer reveals a distinctive distribution of tumor-infiltrating lymphocytes in neuroendocrine tumors and carcinomas
Artificial Intelligence (AI) - powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple negative breast cancer (TNBC)
Artificial intelligence (AI)-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes
Trastuzumab plus FOLFOX for Gemcitabine/Cisplatin refractory HER2-positive biliary tract cancer: a multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)
The Inflamed Immune Phenotype (IIP): a clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types
Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: a phase I study
Robust artificial intelligence-powered imaging biomarker based on mammography for risk prediction of breast cancer.